semaglutide biomarkers alzheimer fails to slow progression of Alzheimer's in highly anticipated trials, Novo Nordisk says GLP-1 receptor agonist fails to

If there's the potential for extra benefits, is there the potential for extra risks with reta too

Furthermore, the REWIND trial demonstrated a 12% reduction in major adverse cardiovascular events (MACE) ( p = 0.026), including among patients without established cardiovascular disease, alongside renoprotective effects evidenced by reductions in albuminuria [56]

Endocrinology 1996, 137:2968-2978

GLP-1 receptor agonist and combination GLP-1/GIP receptor agonist medications are exogenous incretins that mimic their endogenous counterparts, but their significantly longer half-lives allow them to be clinically useful for managing diabetes mellitus type 2 (DMT2) and obesity